CompaniesAntibodies Incorporated

Antibodies Incorporated

active

Davis, CA, United States

Founded 1960

Website

About

Antibodies, Assays, Development Services, Diagnostic kits, etc..

Areas of Focus

Categories

Non-PharmaceuticalContract ResearchContract ResearchContract ResearchAntibodyBiotechServices

Clinical Trials (57)

View all

Total Trials

As Lead Sponsor

As Collaborator

Total Enrollment

10,854

By Phase

NA: 11PHASE3: 6PHASE2: 14PHASE1: 10PHASE4: 1PHASE1/PHASE2: 5PHASE2/PHASE3: 3EARLY_PHASE1: 1

By Status

COMPLETED: 31UNKNOWN: 12TERMINATED: 6RECRUITING: 3WITHDRAWN: 3ACTIVE_NOT_RECRUITING: 2

Clinical Trials Pipeline57 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Today

NCT00016263

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

Phase: Phase 3

Role: Lead Sponsor

Start: Jul 31, 2000

Completion: Dec 31, 2004

NCT00017589

Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia

Phase: Phase 2

Role: Lead Sponsor

Start: Dec 31, 2000

Completion: May 31, 2006

NCT00017589

NCT00017602

Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 31, 2000

Completion: Apr 30, 2009

NCT00017602

NCT00021749

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

Phase: Phase 1/2

Role: Lead Sponsor

Start: Jan 31, 2001

Completion: Not specified

NCT00021749

NCT00636285

Safety and Pharmacokinetics Study in Adults for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2001

Completion: Nov 30, 2001

NCT00024440

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase: Phase 3

Role: Lead Sponsor

Start: Jul 31, 2001

Completion: Feb 28, 2007

NCT00024440

NCT00030641

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

Phase: Phase 2/3

Role: Lead Sponsor

Start: Oct 31, 2001

Completion: Not specified

NCT00030641

NCT00631878

Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110

Phase: Phase 1/2

Role: Lead Sponsor

Start: Nov 30, 2001

Completion: Aug 31, 2003

NCT00054808

Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase: Phase 2

Role: Lead Sponsor

Start: Jun 30, 2002

Completion: Not specified

NCT00054808

NCT00631800

Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110

Phase: Phase 2

Role: Lead Sponsor

Start: May 31, 2003

Completion: Nov 30, 2004

NCT00078234

Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia

Phase: Phase 1/2

Role: Lead Sponsor

Start: Nov 30, 2003

Completion: Sep 30, 2010

NCT00078234

NCT00543205

Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment

Phase: Phase 2/3

Role: Lead Sponsor

Start: Aug 31, 2005

Completion: May 31, 2007

NCT00543231

A Phase I Study of G3139 Subcutaneous in Solid Tumors

Phase: Phase 1

Role: Lead Sponsor

Start: Dec 31, 2005

Completion: Dec 31, 2006

NCT00542893

A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2006

Completion: Sep 30, 2007

NCT00543075

Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function

Phase: Phase 1

Role: Lead Sponsor

Start: May 31, 2006

Completion: Sep 30, 2009

NCT00517218

This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 30, 2006

Completion: Jun 30, 2009

NCT00409383

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 30, 2006

Completion: Jun 30, 2013

NCT00409383

NCT00636545

Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

Phase: Phase 1

Role: Lead Sponsor

Start: May 31, 2007

Completion: Mar 31, 2010

NCT00518895

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

Phase: Phase 3

Role: Lead Sponsor

Start: Jul 31, 2007

Completion: May 31, 2011

NCT00736450

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase: Early Phase 1

Role: Collaborator

Start: Jul 23, 2008

Completion: Oct 9, 2012

NCT00836173

Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase: Phase 2

Role: Collaborator

Start: Jul 31, 2008

Completion: May 31, 2012

NCT00646399

Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis

Phase: Phase 2/3

Role: Lead Sponsor

Start: Mar 31, 2009

Completion: May 31, 2011

NCT01092585

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

Phase: Phase 2

Role: Lead Sponsor

Start: Feb 28, 2010

Completion: Mar 31, 2012

NCT01064713

Phase II Study of Tesetaxel in Metastatic Melanoma

Phase: Phase 2

Role: Collaborator

Start: Feb 28, 2010

Completion: Oct 31, 2014

NCT01064713

NCT01095120

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

Phase: Phase 2

Role: Lead Sponsor

Start: Mar 31, 2010

Completion: Oct 31, 2012

NCT01170975

Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 30, 2010

Completion: Apr 30, 2011

NCT01215877

Tesetaxel for Previously Treated Patients With Bladder Cancer

Phase: Phase 2

Role: Lead Sponsor

Start: Sep 30, 2010

Completion: Dec 31, 2012

NCT01284361

Comparison of Two Intermittent Urinary Catheters

Phase: N/A

Role: Lead Sponsor

Start: Oct 31, 2010

Completion: Aug 31, 2011

NCT01221870

Tesetaxel as First-line Therapy for Metastatic Breast Cancer

Phase: Phase 2

Role: Lead Sponsor

Start: Nov 30, 2010

Completion: Jan 31, 2013

NCT01200342

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

Phase: Phase 2

Role: Collaborator

Start: Dec 31, 2010

Completion: Sep 30, 2013

NCT01296243

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Phase: Phase 2

Role: Lead Sponsor

Start: Feb 28, 2011

Completion: Feb 28, 2015

NCT01315431

A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors

Phase: Phase 1

Role: Lead Sponsor

Start: Mar 31, 2011

Completion: Oct 31, 2012

NCT01293461

Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes

Phase: Phase 1/2

Role: Lead Sponsor

Start: Apr 30, 2011

Completion: Oct 31, 2012

NCT01337310

Study of Tesetaxel in Japanese Patients With Solid Tumors

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2011

Completion: Sep 30, 2012

NCT01348009

Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer

Phase: Phase 1/2

Role: Lead Sponsor

Start: May 31, 2011

Completion: Jan 31, 2014

NCT01413672

Preliminary Evaluation of CASTLE Barrier North American Prototype

Phase: N/A

Role: Lead Sponsor

Start: Aug 31, 2011

Completion: Dec 31, 2011

NCT01530087

Preliminary Evaluation of CASTLE Barrier Prototype UK

Phase: N/A

Role: Lead Sponsor

Start: Jan 31, 2012

Completion: Aug 31, 2012

NCT01567150

Wound Fluid Protease Levels During Use of Novel Wound Dressing

Phase: Phase 4

Role: Lead Sponsor

Start: Feb 29, 2012

Completion: Jan 31, 2014

NCT01573468

Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer

Phase: Phase 2

Role: Lead Sponsor

Start: Apr 30, 2012

Completion: Aug 31, 2014

NCT01609127

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

Phase: Phase 2

Role: Lead Sponsor

Start: May 31, 2012

Completion: Jul 31, 2014

NCT01651260

Assessment of an Endotracheal Tube Securement Device

Phase: N/A

Role: Lead Sponsor

Start: Jul 31, 2012

Completion: Feb 28, 2013

NCT01638104

ANX-042 Healthy Volunteer Dose Escalation Study

Phase: Phase 1

Role: Collaborator

Start: Aug 31, 2012

Completion: Dec 31, 2012

NCT01681290

Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes

Phase: Phase 2

Role: Lead Sponsor

Start: Oct 31, 2012

Completion: Jan 31, 2015

NCT02003404

Preliminary Study of Peel Force and Discomfort of Removal of Adhesive Barriers in Normal and Peristomal Skin

Phase: N/A

Role: Lead Sponsor

Start: Nov 30, 2013

Completion: Feb 28, 2014

NCT02042677

Assessment of a Skin Barrier

Phase: N/A

Role: Lead Sponsor

Start: Jan 31, 2014

Completion: Sep 30, 2014

NCT02401412

The Advocate Study

Phase: N/A

Role: Lead Sponsor

Start: Mar 16, 2015

Completion: Feb 3, 2017

NCT02511600

Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication

Phase: Phase 3

Role: Collaborator

Start: Dec 31, 2015

Completion: Not specified

NCT02511600

NCT02760927

Assessment of a Oral Endotracheal Tube Fastener on Patients Intubated With Oral Endotracheal Tubes

Phase: N/A

Role: Lead Sponsor

Start: Mar 31, 2016

Completion: May 31, 2016

NCT03328182

Assessment of an Oral Endotracheal Subglottic Tube Holder

Phase: N/A

Role: Lead Sponsor

Start: Oct 23, 2017

Completion: Jun 15, 2018

NCT04397055

Oil Consumption and Cholesterol

Phase: N/A

Role: Collaborator

Start: May 14, 2018

Completion: Jun 8, 2021

NCT03715179

Observational Study of Ostomy Consumers

Phase: N/A

Role: Lead Sponsor

Start: Oct 4, 2018

Completion: Feb 28, 2027

NCT03715179

NCT04619992

Consumer Evaluation of Intermittent Catheter Product Modifications

Phase: N/A

Role: Lead Sponsor

Start: Oct 14, 2020

Completion: Aug 17, 2021

NCT06899100

Gentle Warriors Academy Healthy Marriage and Responsible Fatherhood Program Evaluation

Phase: N/A

Role: Collaborator

Start: Apr 1, 2021

Completion: Aug 15, 2025

NCT04924569

Continence Care Registry

Phase: N/A

Role: Lead Sponsor

Start: May 24, 2021

Completion: May 31, 2026

NCT04924569

NCT05686954

Cottonseed Oil Dose Response

Phase: N/A

Role: Collaborator

Start: Mar 1, 2023

Completion: May 31, 2027

NCT06547905

Evaluation of an Ostomy Leakage Detection System

Phase: N/A

Role: Lead Sponsor

Start: Jul 24, 2024

Completion: Nov 15, 2024

NCT06216678

The Effects of Healthy Diets With Plant Oils on Heart and Metabolic Health

Phase: N/A

Role: Collaborator

Start: Sep 9, 2024

Completion: Dec 31, 2025

Hover over trial bars to see details

Recent Trials

NCT06216678Collaborator

The Effects of Healthy Diets With Plant Oils on Heart and Metabolic Health

NARecruiting

52 participants

Started: Sep 9, 2024 · Completed: Dec 31, 2025

NCT06547905Lead Sponsor

Evaluation of an Ostomy Leakage Detection System

NACompleted

22 participants

Started: Jul 24, 2024 · Completed: Nov 15, 2024

NCT05686954Collaborator

Cottonseed Oil Dose Response

NARecruiting

80 participants

Started: Mar 1, 2023 · Completed: May 31, 2027

NCT04924569Lead Sponsor

Continence Care Registry

N/AActive, not recruiting

600 participants

Started: May 24, 2021 · Completed: May 31, 2026

NCT06899100Collaborator

Gentle Warriors Academy Healthy Marriage and Responsible Fatherhood Program Evaluation

NAActive, not recruiting

709 participants

Started: Apr 1, 2021 · Completed: Aug 15, 2025

View all 57 trials →

Locations (1)

Headquarters

Davis, CA, United States

Map

Loading map...